{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4","upperLimit":"12","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"From date of initial registration to date of progression/relapse of disease (\\> 25% increase from baseline in myeloma protein production or other signs of disease progression such as hypercalcemia, etc.) or death from any cause, whichever came first, up to 5 years","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction (per 21-day cycle): Bortezomib - 1.0 mg/m2 (Days 1, 4, 8, and 11). Dexamethasone - 20 mg/d PO (Days 1, 2, 4, 5, 8, 9, 11, and 12). Thalidomide 100 mg (Days 1-21).\n\nMaintenance (per 28-day cycle): thalidomide 100mg (Days 1-28). Dexamethasone 40 mg Days 1-4.","id":"OG000","title":"Bortezomib With Thalidomide and Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"With ninety patients, we will have 82% power to rule out a null hypothesis of a 12-month median survival versus an alternative hypothesis of an 18-month median survival at a significance level of 5%.","reportingStatus":"POSTED","timeFrame":"about 12-18 months","title":"Progression-Free Survival","type":"SECONDARY","unitOfMeasure":"Months"}